Summary: In adults with type 2 diabetes and chronic kidney disease on stable ACE inhibitor or ARB therapy, semaglutide 1.0…
Browsing: Heart Failure & Renal Protection
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles,…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly…
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.